We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.72 | -0.56% | 128.50 | 129.93 | 127.80 | 129.43 | 5,895,709 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Surface Oncology Inc. on Wednesday said it would collaborate with Merck & Co. to study its SRF617 investigational antibody therapy in combination with Merck's Keytruda cancer drug in patients with solid tumors.
Surface, a Cambridge, Mass., clinical-stage immuno-oncology company, said the companies will study the combination as a component of a first-in-human phase 1/1b study of SRF617.
Surface said the study would focus on patients with gastric cancer and those who have developed resistance to checkpoint inhibition, both areas of high unmet need.
Shares of Surface, which closed Tuesday at $2.66, surged 42% in premarket trading Wednesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 20, 2020 07:50 ET (11:50 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
